Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Associated Therapies: -

Clinical Trials

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: ofatumumab
Drug: bendamustine

First Posted Date: 2012-09-25

Last Posted Date: 2018-02-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT01691807

Locations: 🇺🇸
Novartis Investigative Site, Morgantown, West Virginia, United States

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Phase 1

Conditions: Multiple Myeloma

Interventions: Drug: Bendamustine
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2012-09-18

Last Posted Date: 2013-04-05

Lead Sponsor: Gruppo Italiano Studio Linfomi

Target Recruit Count: 60

Registration Number: NCT01686386

Locations: 🇮🇹
U. O. C. Ematologia - Azienda Ospedaliera Cosenza, Cosenza, Italy

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

Phase 3

Conditions: Chronic Lymphocytic Leukaemia

Interventions: Drug: Ofatumumab
Drug: Bendamustine
Drug: Chlorambucil

First Posted Date: 2012-09-05

Last Posted Date: 2012-10-15

Lead Sponsor: University of Liverpool

Target Recruit Count: 670

Registration Number: NCT01678430

Locations: 🇬🇧
Derriford Hospital, Plymouth, Devon, United Kingdom
🇬🇧
Torbay Hospital, Torquay, Devon, United Kingdom
🇬🇧
Dorset County Hospital, Dorchester, Dorset, United Kingdom

and more 23 locations

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Bendamustine
Drug: Rituximab
Drug: Obinutuzumab
Drug: Venetoclax

First Posted Date: 2012-08-24

Last Posted Date: 2020-10-14

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 84

Registration Number: NCT01671904

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of California San Diego Medical Center, La Jolla, California, United States
🇫🇷
Hopital Saint Eloi, Montpellier, France

and more 9 locations

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Phase 1

Completed

Conditions: Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Anti-Thymocyte Globulin
Drug: Bendamustine Hydrochloride
Drug: Fludarabine Phosphate
Biological: Inotuzumab Ozogamicin
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: Rituximab
Drug: Tacrolimus

First Posted Date: 2012-08-14

Last Posted Date: 2024-07-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT01664910

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Bendamustine
Drug: Cytarabine

First Posted Date: 2012-08-10

Last Posted Date: 2024-06-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT01661881

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)

Phase 1

Completed

Conditions: Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: Bendamustine
Drug: Neulasta

First Posted Date: 2012-08-06

Last Posted Date: 2020-07-17

Lead Sponsor: Columbia University

Target Recruit Count: 71

Registration Number: NCT01657331

Locations: 🇺🇸
Center for Lymphoid Malignancies at CUMC, New York, New York, United States
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Phase 2

Withdrawn

Conditions: Leukemia
Lymphoma

Interventions: Drug: Bendamustine

First Posted Date: 2012-07-25

Last Posted Date: 2012-11-08

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01649622

Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

Phase 2

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Bendamustine
Drug: Ofatumumab

First Posted Date: 2012-06-22

Last Posted Date: 2017-11-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 22

Registration Number: NCT01626352

Locations: 🇺🇸
Woodlands Medical Specialists, Pensacola, Florida, United States
🇺🇸
Florida Cancer Specialists North, Saint Petersburg, Florida, United States
🇺🇸
Space Coast Cancer Center, Titusville, Florida, United States

and more 8 locations

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Ibrutinib
Drug: Bendamustine hydrochloride
Drug: Rituximab
Drug: Placebo

First Posted Date: 2012-06-04

Last Posted Date: 2020-03-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 578

Registration Number: NCT01611090

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy